Lancet Regional Health-Europe最新文献

{"title":"Antibody-drug conjugates in cancer treatment: from molecular design to clinical implementation","authors":"André Mansinho ,&nbsp;Joana Albuquerque ,&nbsp;Chiara Barigazzi ,&nbsp;Emiliano Calvo","doi":"10.1016/j.lanepe.2026.101634","DOIUrl":"10.1016/j.lanepe.2026.101634","url":null,"abstract":"<div><div>Antibody-drug conjugates (ADCs) are a promising innovation in precision oncology, combining tumor-targeting antibodies with potent cytotoxic molecules to improve their therapeutic index and outcomes. This Series paper explores the evolution of ADCs from early development to current EMA-approved therapies, highlighting the key advances in design and mechanisms of action. We expand on the critical components of ADCs (linkers, antibodies and payloads) and how the evolution of the linker technologies, site-specific conjugation and novel payloads are increasingly enhancing their therapeutic index. Pivotal clinical trials in solid and hematologic cancers are summarised, alongside the caveats related to efficacy, safety and accessibility. Challenges such as narrow therapeutic windows driven by dose-limiting toxicities/off-target effects and high production costs are discussed, as well as future directions including combination therapies, overcoming resistance mechanisms, and biomarker-guided patient selection. The need for ongoing innovation and collaboration is key to maximizing the clinical potential of ADCs in Oncology.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101634"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex–specific associations between frailty and long-term outcomes in patients with acute myocardial infarction: a national population-based study","authors":"Hasan Mohiaddin ,&nbsp;Chijioke Horatio Mosanya ,&nbsp;Claire Lawson ,&nbsp;Kamlesh Khunti ,&nbsp;Angela Wood ,&nbsp;Iain B. Squire ,&nbsp;Gerry P. McCann ,&nbsp;Abdulla A. Damluji ,&nbsp;Sergio Buccheri ,&nbsp;Mohamad A. Alkhouli ,&nbsp;Mamas A. Mamas ,&nbsp;Muhammad Rashid","doi":"10.1016/j.lanepe.2026.101612","DOIUrl":"10.1016/j.lanepe.2026.101612","url":null,"abstract":"<div><h3>Background</h3><div>Frailty and female sex are both recognised independent predictors of adverse outcomes after acute myocardial infarction (AMI). While females presenting with AMI are known to have a higher burden of frailty than males, it is unknown whether this fully explains sex-based disparities in outcomes, or if the prognostic impact of frailty itself differs between the sexes.</div></div><div><h3>Methods</h3><div>We conducted a retrospective national cohort study using data from the Myocardial Ischaemia National Audit Project (MINAP), linked to hospital admission and mortality registries in England and Wales between 2005 and 2019. Frailty was assessed using the Secondary Care Administrative Records Frailty (SCARF) index and categorised as fit, mild, moderate, or severe. Multivariable Cox proportional hazards models were used with a primary outcome of all-cause mortality at 1-year.</div></div><div><h3>Findings</h3><div>Of 931,133 patients with AMI, 317,967 (34.1%) were female. Frailty was more prevalent in females than in males (severe frailty: 53,065 [16.7%] vs. 64,018 [10.4%]). Males received more intensive therapeutic care across all frailty levels. After multivariable adjustment, the relationship between severe frailty and 1-year all-cause mortality was 26% greater in males than in females (relative hazard ratio [rHR]: 1.26, 95% CI 1.19–1.32, P-interaction &lt;0.001). This corresponded to an adjusted absolute risk difference of 1.19% (95% CI 0.58%–1.79%)</div></div><div><h3>Interpretation</h3><div>In this national AMI cohort, while frailty was more prevalent in females, its association with 1-year mortality was significantly greater in males. This sex-specific effect of frailty challenges current risk-assessment paradigms and underscores the need for sex-informed care pathways.</div></div><div><h3>Funding</h3><div><span>National Institute for Health and Care Research</span> and <span>British Heart Foundation Centre of Research Excellence</span>, Leicester.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101612"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146161966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corticosteroids for Mycoplasma pneumoniae community-acquired pneumonia: promising evidence from a randomised controlled trial","authors":"Bijan Teja ,&nbsp;John C. Marshall","doi":"10.1016/j.lanepe.2026.101677","DOIUrl":"10.1016/j.lanepe.2026.101677","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101677"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migration control enters the clinic: a public health red line","authors":"The Lancet Regional Health – Europe","doi":"10.1016/j.lanepe.2026.101703","DOIUrl":"10.1016/j.lanepe.2026.101703","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101703"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in cell therapy for solid tumours: European perspective and future directions","authors":"Victor Moreno ,&nbsp;Fiona Thistlethwaite ,&nbsp;Ramón Yarza ,&nbsp;Willemijn S. Tak ,&nbsp;Kok Haw Jonathan Lim ,&nbsp;John B.A.G. Haanen","doi":"10.1016/j.lanepe.2026.101590","DOIUrl":"10.1016/j.lanepe.2026.101590","url":null,"abstract":"<div><div>Cell therapy has revolutionised the landscape of cancer treatment, with therapies such as Chimeric Antigen Receptor T cells (CAR-T cells), showing remarkable efficacy in haematological malignancies, and approaches such as Tumour Infiltrating Lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) showing increasing promise in solid tumours. The recent US FDA approvals of lifileucel (a TIL therapy for advanced melanoma) and afamitresgene autoleucel (a TCR therapy targeting MAGE-A4 in synovial sarcoma) mark the first regulatory recognition of cell therapies for solid tumours and signal a new era for oncology. Europe has played a central role in these advances, leading pivotal phase 3 trials and pioneering hospital-exemption-based manufacturing programmes. However, the continent still faces major challenges, including fragmented regulatory frameworks, high manufacturing costs, and inequitable patient access across member states. Emerging innovations such as gene-edited, allogeneic, and iPSC-derived cell products promise to address current limitations by improving scalability, safety, and time-to-treatment. This Series paper examines the latest advancements in cell therapy, focussing on the European experience, while comparing global trends. We discuss challenges specific to Europe, such as regulatory frameworks, manufacturing scalability, and disparities in access. Emphasis is placed on emerging innovations like gene-edited and allogeneic therapies, as well as future directions for integrating cell therapies into mainstream oncology. We conclude with recommendations for overcoming barriers related to cost, toxicity management, and equitable access across Europe.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101590"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncolytic viruses and neoantigen vaccines: opportunities and challenges in priming antitumour immunity","authors":"André Mansinho ,&nbsp;Joana Albuquerque ,&nbsp;Emiliano Calvo","doi":"10.1016/j.lanepe.2026.101659","DOIUrl":"10.1016/j.lanepe.2026.101659","url":null,"abstract":"<div><div>In the past years the therapeutic landscape in Oncology has been expanded, creating new possibilities in achieving superior tumor specificity and minimizing systemic toxicity. Amidst these, oncolytic viruses and cancer vaccines have risen as ingenious approaches that harness unique mechanisms of action, exploiting the immune system to destroy malignancies. Oncolytic viruses, typically modified to selectively infect cancer cells, ultimately lead to their destruction, offering both the benefit of direct cytolysis and the subsequent activation of our immune system, which might therefore improve durable responses. On the other hand, cancer vaccines, aim to provoke a targeted immune response against antigens that are tumor specific, ultimately enhancing immune surveillance and reducing the risk of relapse. Despite the promising rationale behind these approaches, there are significant challenges in areas such as the optimisation of therapeutic delivery, tackling tumor immune evasion and managing new emergent adverse events. This Series paper discusses the potential impact of these strategies on the current landscape of cancer treatment, while also covering the challenges that might emerge in clinical implementation.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101659"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bivalent RSV prefusion vaccine effectiveness against hospitalisation in older adults: meta-analysis of case–control studies in England, Wales, Scotland, and Northern Ireland","authors":"Magda Bucholc ,&nbsp;Safraj Shahul Hameed ,&nbsp;Simon Cottrell ,&nbsp;Anna A. Mensah ,&nbsp;Kirsty Morrison ,&nbsp;Heather J. Whitaker ,&nbsp;Jaime Borjas-Howard ,&nbsp;Alec Cobbold ,&nbsp;Kimberly Marsh ,&nbsp;Ross McQueenie ,&nbsp;Nick Andrews ,&nbsp;Mark G. O'Doherty ,&nbsp;Emma Dickson ,&nbsp;Chris Robertson ,&nbsp;Victoria McClure ,&nbsp;Polani Rubeshkumar ,&nbsp;Clare Brown ,&nbsp;Joshua Menadue ,&nbsp;Christopher Johnson ,&nbsp;Malorie Perry ,&nbsp;Declan T. Bradley","doi":"10.1016/j.lanepe.2026.101620","DOIUrl":"10.1016/j.lanepe.2026.101620","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in older adults. In 2023, the RSVpreF vaccine was licenced and recommended for adults through the UK's national immunisation programmes. Real-world evidence on vaccine effectiveness (VE) across different populations and healthcare settings is limited.</div></div><div><h3>Methods</h3><div>We conducted a retrospective, multi-nation, test-negative design analysis to evaluate RSVpreF VE against hospitalisation in adults aged 74–79 years across England, Wales, Scotland, and Northern Ireland during the 2024–25 RSV season. Laboratory testing, admission, and vaccination data were linked at the individual patient level. Eligible cases were hospitalised individuals with laboratory-confirmed RSV, and controls were RSV-negative hospitalised patients; SARS-CoV-2- and influenza-positive controls were excluded in the primary analysis. Nation-specific VE estimates were derived using multivariable logistic regression, adjusted for epidemiological week of specimen collection, and combined using fixed-effects meta-analysis with inverse-variance weighting. Sensitivity analyses included redefinition of controls and leave-one-nation-out analyses.</div></div><div><h3>Findings</h3><div>A total of 11,117 adults were included (6528 in England, 942 in NI, 1462 in Scotland, 2185 in Wales). Overall, 3896 (35.0%) had received RSVpreF. Across nations, 826 RSV-positive cases were identified, of whom 726 (87.9%) were unvaccinated. Adjusted VE against RSV-related hospitalisation was 74% (95% confidence interval [CI] 68–80) in England, 77% (30–95) in NI, 81% (60–91) in Scotland, and 82% (43–94) in Wales. Pooled fixed-effects VE was 75% (69–80; <em>I</em>^<em>2</em> = 0%). VE estimates from sensitivity analyses were robust to the inclusion of vaccine-preventable respiratory infection controls and adjustment for vaccination status. Leave-one-nation-out sensitivity analysis showed that excluding England increased pooled VE to 81% (66–89), whereas exclusion of NI, Scotland, or Wales had minimal impact (75%, 68–80 to 69–80).</div></div><div><h3>Interpretation</h3><div>RSVpreF vaccination provides high real-world protection against RSV-related hospitalisation in adults across the UK.</div></div><div><h3>Funding</h3><div>This study received no specific funding.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101620"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to diagnosis and treatment of obstructive sleep apnoea using mandibular jaw movement monitoring versus polysomnography: an open-label, multicentre, randomised, controlled trial","authors":"Jean-Louis Pépin ,&nbsp;Renaud Tamisier ,&nbsp;Marc Manceau ,&nbsp;Katleen Denoncin ,&nbsp;Arnaud Prigent ,&nbsp;Maxime Patout ,&nbsp;Hervé Pégliasco ,&nbsp;Frédéric Gagnadoux ,&nbsp;Jean-Benoît Martinot ,&nbsp;Matthieu Roustit","doi":"10.1016/j.lanepe.2026.101637","DOIUrl":"10.1016/j.lanepe.2026.101637","url":null,"abstract":"<div><h3>Background</h3><div>Obstructive sleep apnoea (OSA) is often underdiagnosed, highlighting the need for scalable diagnostic alternatives. The SUNSAS study compared a new device for at-home diagnosis of OSA (artificial intelligence [AI]-supported analysis of mandibular jaw movements [MJM]) with polysomnography (PSG) for time to diagnosis and treatment, and patient-reported outcomes.</div></div><div><h3>Methods</h3><div>This prospective, multicentre, randomised, controlled, open-label study was conducted in France (October 2021–October 2024). Adults aged 18–80 years with suspected OSA were randomised (1:1) to undergo diagnostic testing using MJM monitoring (Sunrise) or PSG. Primary endpoints were assessed using hierarchical testing: 1. daytime sleepiness (Epworth Sleepiness Scale [ESS] score) at 3 months post-diagnosis and time to diagnosis; 2. time to treatment; and 3. daytime sleepiness at 3 months post-randomisation. Secondary endpoints included quality of life (Short Form-36, Quebec Sleep Questionnaire), work productivity (Work Productivity and Activity Impairment questionnaire), and positive airway pressure therapy adherence at 3 months after treatment initiation.</div></div><div><h3>Findings</h3><div>Of 849 participants randomised (58·7% male, median age 50 years, body mass index 28·0 kg/m², apnoea-hypopnoea index 15·2/h), 774 received a diagnosis: 133 no OSA, 239 mild OSA, 220 moderate OSA, and 182 severe OSA. Median time to diagnosis (15 vs. 106 days) and to treatment initiation (50 vs. 124 days) were significantly shorter with MJM analysis versus PSG (both p &lt; 0·01). MJM-based diagnosis was noninferior to PSG in reducing ESS at 3 months after diagnosis (−2·26 vs. −2·29; 95% confidence interval [CI] for difference −0·85, 0·79; p = 0·01), and superior at 3 months post-randomisation (between-group difference: −1·51 (95% CI −2·17, −0·85); p &lt; 0·01). Secondary endpoints also favoured the MJM group.</div></div><div><h3>Interpretation</h3><div>OSA diagnosis based on MJM monitoring with AI-supported analysis is noninferior to PSG in reducing daytime sleepiness at 3 months after diagnosis, while significantly accelerating time to diagnosis and treatment initiation, resulting in earlier improvement in daytime sleepiness.</div></div><div><h3>Funding</h3><div>Sunrise, with support from the <span>French Ministry of Health</span> through the <span><em>Forfait Innovation</em> programme</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101637"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung aeration and gas exchange in preterm infants developing moderate-to-severe bronchopulmonary dysplasia: a multicentre prospective study from the PATH-BPD cohort","authors":"Daniele De Luca ,&nbsp;Luca Bonadies ,&nbsp;Costanza Neri ,&nbsp;Barbara Loi ,&nbsp;Teresa Maria Silva-Garcia ,&nbsp;Guillermo Ramos Noguera ,&nbsp;Laura Vivalda ,&nbsp;Giulia Res ,&nbsp;Maria de las Nieves Cidoncha-Fuertes ,&nbsp;Carlos Baena-Palomino ,&nbsp;Lorenzo Zanetto ,&nbsp;Luca Vedovelli ,&nbsp;Dario Gregori ,&nbsp;Eugenio Baraldi ,&nbsp;Almudena Alonso-Ojembarrena","doi":"10.1016/j.lanepe.2025.101584","DOIUrl":"10.1016/j.lanepe.2025.101584","url":null,"abstract":"<div><h3>Background</h3><div>We lack data about the early evolution of lung pathophysiology in infants developing moderate-to-severe broncho-pulmonary dysplasia (msBPD). We aimed to describe lung aeration and gas exchange during the early phase of msBPD development and identify the critical moments at which they change.</div></div><div><h3>Methods</h3><div>Prospective, multicentre, cohort study performed in three European centres enrolling preterm (≤30 weeks’ gestation) infants evaluated at 10, 21, 28 days (D) of life and 34 and 36 weeks (W) post-menstrual age, while receiving as little invasive ventilation as possible. Lung aeration was assessed with quantitative lung ultrasound. Pulse oximetry and transcutaneous blood gas measurements were used to calculate the SpO₂/FiO₂ and PtcO₂/FiO₂ ratios. msBPD was defined using NIH-2001, NICHD-2018 and Jensen definitions.</div></div><div><h3>Findings</h3><div>347 infants were studied, of which 80, 79 and 89 had msBPD, using the three definitions, respectively. Lung aeration and oxygenation were always poorer, since D10, in patients with msBPD than in those without it. The difference in lung aeration (β ranging from +0.009 (95% CI: 0; 0.01) to +0.012 (95% CI: 0.01; 0.02), depending on the used definition, <em>p</em> &lt; 0.001) and carbon dioxide (β ranging from +0.01 (95% CI: 0; 0.02) to +0.014 (95% CI: 0.01; 0.02), depending on the used definition, <em>p</em> &lt; 0.001) between patients with and without msBPD increased overtime. Results were similar regardless of the BPD definition. The strongest discrimination was obtained by the lung aeration evolution (β(t) = 0.227 (95% CI: 0.152, 0.302), <em>p</em> &lt; 0.001) with a peak at 26 days.</div></div><div><h3>Interpretation</h3><div>Patients who develop msBPD consistently demonstrate early and typical pathophysiological phenotypes regardless of the BPD definition. These data highlight critical moments in the development of msBPD and are not captured by currently available BPD definitions.</div></div><div><h3>Funding</h3><div>Only institutional funding to support the author's working time was used.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"63 ","pages":"Article 101584"},"PeriodicalIF":13.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Code Against Cancer 5th edition: 14 ways you can help prevent cancer","authors":"Carolina Espina ,&nbsp;David Ritchie ,&nbsp;Elio Riboli ,&nbsp;Hans Kromhout ,&nbsp;Silvia Franceschi ,&nbsp;Iris Lansdorp-Vogelaar ,&nbsp;Theresa M. Marteau ,&nbsp;Ioanna Bakogianni ,&nbsp;Nadia Vilahur ,&nbsp;Catherina J. Alberts ,&nbsp;Urska Ivanus ,&nbsp;Ariadna Feliu ,&nbsp;Erica D'Souza ,&nbsp;Hajo Zeeb ,&nbsp;Giota Mitrou ,&nbsp;Tit Albreht ,&nbsp;Joakim Dillner ,&nbsp;Jérôme Foucaud ,&nbsp;Marta Manczuk ,&nbsp;Jose María Martin-Moreno ,&nbsp;Joachim Schüz","doi":"10.1016/j.lanepe.2026.101592","DOIUrl":"10.1016/j.lanepe.2026.101592","url":null,"abstract":"<div><div>Despite the growing cancer burden in the European Union, public awareness of effective prevention is low. In response, Europe's Beating Cancer Plan has supported the development of the 5th edition of the European Code Against Cancer (ECAC5). Using a transparent, stepwise decision-making process, around 80 experts reviewed the latest scientific evidence on cancer prevention and used modern communication strategies to update the previous edition. An innovation in ECAC5 is the inclusion of population-level recommendations, aiming to structurally influence the systems that shape individual choices and improve environmental conditions to which all citizens are involuntarily exposed. ECAC5 includes 14 actionable, evidence-based recommendations for individuals to reduce their cancer risk alongside their respective policy recommendations. All are presented through equity lens, with attention to co-benefits for preventing other non-communicable diseases and tailoring messages to diverse audiences. Clear evidence-based statements on cancer risks factors and effective preventive interventions will empower citizens to make healthier choices, call policymakers to act, foster public support for effective policies, and contribute to more effective cancer prevention.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"63 ","pages":"Article 101592"},"PeriodicalIF":13.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}